Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
Year: 2023
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious…
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious…
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline…
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline…
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a…
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a…
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…